Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces clinically significant weight loss (mean 6.2–12.9 kg) and glycemic control (HbA1c reduction -1.87 to -2.59%) in adults with type 2 diabetes, with efficacy increasing with dose up to 15 mg weekly.
Tirzepatide is a once-weekly injection for type 2 diabetes that helps lower blood sugar and lose weight. It starts at a low dose (2.5 mg) to minimize side effects like nausea, which usually improve over time. The dose can be increased every 4 weeks up to 15 mg based on tolerance and need. It is approved for adults with T2DM, especially those who are overweight or obese, and works by mimicking hormones that regulate blood sugar and appetite. Patients should follow dietary advice (smaller, low-fat meals) to manage GI side effects and monitor blood glucose, especially if taking other diabetes medications like insulin or sulfonylureas.
All five studies demonstrated that tirzepatide treatment achieved sustained statistically significant and clinically meaningful reductions from baseline in hemoglobin A1c (HbA1c) (– 1.87 to – 2.59%, – 20 to – 28 mmol/mol) and in body weight (– 6.2 to – 12.9 kg), compared to either placebo or active comparators (semaglutide 1 mg, insulin degludec and insulin glargine).
Why this rating
Based on phase 3 SURPASS clinical trial program involving multiple large-scale randomized controlled trials.
Source
Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects
Luis Alberto Vázquez et al. · Diabetes Therapy · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →